Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026

Rhea-AI Summary

Zymeworks (Nasdaq: ZYME) will report first quarter 2026 financial results after market close on May 7, 2026. Management will host a conference call and live webcast the same day at 4:30 PM ET to discuss results and provide a corporate update. Webcast replay and dial-in details will be available on the company website.

News Market Reaction – ZYME

-1.91%

-1.91% Session close to close

In the Apr 16 session, ZYME declined 1.91%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timetable for Zymeworks’ Q1 2026 financial results on May 7, 2026 and a c...

Analysis

This announcement sets the timetable for Zymeworks’ Q1 2026 financial results on May 7, 2026 and a conference call at 4:30 pm ET. A prior earnings-date notice produced a 1.49% move, suggesting the market has reacted modestly to similar updates. Investors may focus on how upcoming commentary connects to recent clinical designations, leadership changes, and the existing royalty-backed financing structure when reviewing the forthcoming results and corporate update.

Key Figures

Q1 2026 results date: May 7, 2026 Earnings call time: 4:30 pm ET

2 metrics

Q1 2026 results date May 7, 2026 First quarter 2026 financial results to be reported after market close

Earnings call time 4:30 pm ET Conference call and webcast on May 7, 2026

Previous Conferences,earnings date Reports

1 past event · Latest: Feb 12 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 12	Earnings date set	Neutral	+1.5%	Scheduled Q4 and full-year 2025 results and earnings call details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior earnings-date scheduling news saw a modest positive move of 1.49%, suggesting a mildly constructive reaction pattern to similar announcements.

Recent Company History

Recent Zymeworks news featured clinical, partnership, and leadership milestones, including Fast Track designation for ZW191, new executive hires, and upcoming investor conferences. For tag-matched events, the key comparable item is the Feb 12, 2026 announcement of the Q4 and full-year 2025 earnings date, which led to a 1.49% move. Today’s Q1 2026 earnings-date notice continues this cadence of scheduled updates and conference calls for financial disclosures.

Key Terms

biotherapeutics

1 terms

biotherapeutics medical

"developing a diverse pipeline of novel, multifunctional biotherapeutics"

Biotherapeutics are medicines made from living cells or biological molecules—such as proteins, antibodies, vaccines, or engineered cells and genes—designed to prevent, treat, or cure disease by working with the body’s natural systems. They matter to investors because they can offer groundbreaking, high-value treatments but also come with higher development, manufacturing and regulatory complexity, so their commercial success can drive large stock moves like a breakthrough product or a failed trial.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its first quarter 2026 financial results after market close on May 7, 2026. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 7, 2026 at 4:30 pm Eastern Time (ET).

The event will be webcast live with dial-in details and webcast replays available on Zymeworks’ website at https://ir.zymeworks.com/events-and-presentations.

About Zymeworks Inc.

Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. The Company’s asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera^® (zanidatamab-hrii) and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is also building a portfolio of healthcare assets that can generate strong cash flows, while supporting the development of innovative medicines. Zymeworks engineered and developed Ziihera, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

Contacts:

Investor Inquiries:
Shrinal Inamdar
Vice President, Investor Relations
(604) 678-1388
ir@zymeworks.com   

Media Inquiries:
Diana Papove
Vice President, Corporate Communications
(604) 678-1388
media@zymeworks.com

FAQ

When will Zymeworks (ZYME) report first quarter 2026 results and hold the conference call?

Zymeworks will report Q1 2026 results after market close on May 7, 2026 and host a call at 4:30 PM ET. According to Zymeworks, the management webcast and dial-in details will be available on the company investor website for live participation and replay.

How can investors access the Zymeworks (ZYME) May 7, 2026 webcast and replay?

Investors can access the live webcast and replay via the Zymeworks investor events page on the company website. According to Zymeworks, dial-in details and webcast replays will be posted at https://ir.zymeworks.com/events-and-presentations for on-demand listening after the call.

What will Zymeworks (ZYME) management discuss during the May 7, 2026 conference call?

Management will discuss first quarter 2026 financial results and provide a corporate update during the May 7 call. According to Zymeworks, the session will cover the company’s financial performance and a business update, with time for investor questions via the webcast or dial-in.

What time is the Zymeworks (ZYME) Q1 2026 earnings call scheduled on May 7, 2026?

The Zymeworks earnings call is scheduled for 4:30 PM Eastern Time on May 7, 2026 following the after-market release. According to Zymeworks, the timing allows the company to release financial results after market close and then present details on the conference call and webcast.

Will Zymeworks (ZYME) provide dial-in details for analysts and investors for the May 7, 2026 call?

Yes, dial-in details for analysts and investors will be provided for the May 7 call and posted online by the company. According to Zymeworks, both live dial-in access and a webcast replay will be available on the investor events and presentations webpage.